A commercial partnership deal is what can show a clear picture the MM (mango) necture.
MM needs to now talk abou the partnership deal, given the results meeting the objective and extending what was known in 2018.
In 2018, MM told licensing deal is what is signed on the basis of 2018 results, and SP was $0.4+/s.
In 2024, there must be more than licensing deal, and MM must introduce/unveil the BP that has been guidign the trials and waiting for the trials. MM needs to tell in public that the BP is happy with the Prelim, and happy to partiall fund the biotron prior to the complete results.
Ann: BIT225 Phase 2 HIV Efficacy Trial Meets Primary Objectives, page-59
-
- There are more pages in this discussion • 57 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BIT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.4¢ |
Change
-0.002(4.35%) |
Mkt cap ! $38.79M | |||
| Open | High | Low | Value | Volume |
| 4.5¢ | 4.5¢ | 4.2¢ | $73.19K | 1.696M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 300000 | 4.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.5¢ | 755000 | 1 |
View Market Depth
| Last trade - 14.25pm 25/06/2024 (20 minute delay) ? |
| BIT (ASX) Chart |